Reaching positive milestones in gene therapy has been difficult since a highly publicized death in 1999,1 but some have succeeded. A major break came this year when researchers in Italy and Israel reported successfully treating two patients with ADA-SCID, a form of severe combined immunodeficiency that results from a defective gene for adenosine deaminase (ADA).2 In 2000--in the wake of gene therapy's darkest hour--a French group reported similar results for X-linked SCID, a form of the disease caused by a mutation in the common cytokine receptor gamma chain...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?